Combination of glycosphingosomes and liposomal doxorubicin shows increased activity against dimethyl-α-benzanthracene-induced fibrosarcoma in mice.
The present study aimed to assess the antitumor effect of glycosphingolipid-incorporated liposomes (glycosphingosomes) in combination with liposomal doxorubicin (Lip-Dox) in a mouse model of fibrosarcoma. Glycosphingosomes were prepared by incorporating glycosphingolipids isolated from Sphingomonas paucimobilis into the liposomes of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, cholesterol, and cardiolipin. Tumors were induced by administering dimethyl-α-benzanthracene, and tumor-bearing mice were treated with various formulations of Dox, including free Dox, Lip-Dox, or glycosphingosomes + Lip-Dox. Mice were observed for 90 days to monitor their survival and tumor size. Free Dox, but not Lip-Dox or a combination of glycosphingosomes and Lip-Dox, caused the substantial depletion of leukocytes and significantly increased the levels of lactate dehydrogenase and creatinine kinase in mice. Tumor-bearing mice treated with a combination of glycosphingosomes and Lip-Dox showed restricted tumor growth and increased survival when compared to those treated with free Dox or Lip-Dox. The results of the present study suggest that a combination of glycosphingosomes and Lip-Dox may prove to be very effective in the treatment of tumors.
College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia.
Masood A
MA
Khan
College of Pharmacy, Qassim University, Buraydah, Saudi Arabia.
Ahmed N
AN
Aljarbou
College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia.
Yousef H
YH
Aldebasi
College of Medicine, Qassim University, Buraydah, Saudi Arabia.
Mohammed S
MS
Alorainy
College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia.
Arif
A
Khan
D015060:1,2-Dipalmitoylphosphatidylcholine / Q000031:analogs & derivatives* / Q000737:chemistry; D015127:9,10-Dimethyl-1,2-benzanthracene / Q000633:toxicity*; D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D002626:Chemistry, Pharmaceutical; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005354:Fibrosarcoma / Q000139:chemically induced* / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D011092:Polyethylene Glycols / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D016019:Survival Analysis
C506643:liposomal doxorubicin; D015060:1,2-Dipalmitoylphosphatidylcholine; C081581:colfosceril palmitate; D011092:Polyethylene Glycols; D015127:9,10-Dimethyl-1,2-benzanthracene; D004317:Doxorubicin
NKT cells; chemotherapy; glycosphingolipids; tumors